Yesterday it was reported that the CEO of Arrowhead Research (ARWR), Christopher Richard Anzalone, exercised options to sell 112,650 ARWR shares at $5.10 a share, for a total transaction value of $3.22M. The options were close to expired and Christopher Richard Anzalone disposed stocks.
Following Christopher Richard Anzalone’s last ARWR Sell transaction on May 29, 2019, the stock climbed by 3.1%. In addition to Christopher Richard Anzalone, one other ARWR executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Arrowhead Research’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $42.7 million and quarterly net profit of $20.34 million. In comparison, last year the company earned revenue of $727.4K and had a GAAP net loss of $15.61 million. The company has a one-year high of $36.80 and a one-year low of $10.41. ARWR’s market cap is $2.68B and the company has a P/E ratio of 61.90.
The insider sentiment on Arrowhead Research has been negative according to 43 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Christopher Richard Anzalone’s trades have generated a -29.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
